Abstract
Founded in 1904, Fox Chase Cancer Center remains committed to its mission. It is one of 41 centers in the country designated as a Comprehensive Cancer Center by the National Cancer Institute, is a founding member of the National Comprehensive Cancer Network, holds the magnet designation for nursing excellence, is one of the first to establish a family cancer risk assessment program, and has achieved national distinction because of the scientific discoveries made there that have advanced clinical care. Two of its researchers have won Nobel prizes. The Genitourinary Division is nationally recognized and viewed as one of the top driving forces behind the growth of Fox Chase due to its commitment to initiating and participating in clinical trials, its prolific contributions to peer-reviewed publications and presentations at scientific meetings, its innovations in therapies and treatment strategies, and its commitment to bringing cutting-edge therapies to patients.
Original language | English |
---|---|
Pages (from-to) | 887-891 |
Number of pages | 5 |
Journal | Future Oncology |
Volume | 12 |
Issue number | 7 |
DOIs | |
State | Published - Apr 2016 |
Keywords
- Fox Chase Cancer Center
- bladder cancer
- clinical trials
- genitourinary cancer
- immunotherapy
- kidney cancer
- precision medicine
- prostate cancer
- targeted therapy